Aufrufe
vor 2 Jahren

Wellness Foods + Supplements 3/2021

Wellness Foods & Supplements is the first European magazine devoted exclusively to health ingredients, nutraceutical foods and beverages. Questions about the trade magazine Wellness Foods & Supplements? Interested in subscribing or advertising? The board of editors at Wellness Foods & Supplements kindly remains at your disposal.

Formulation of

Formulation of nutraceuticals Photo © : Shutterstock/SewCream Nutraceutical tablets with enhanced properties Omya’s new mineral excipients enable manufacturers to produce tablets with improved technical characteristics and ease of use The nutraceutical world is evolving fast. Today, there are multiple ways of delivering dietary supplements, many of which have a high number of active ingredients in their formulation. For this reason, the production of tablets can be challenging and often requires high compaction forces to bond all components together. Also, more and more natural substances such as herbal extracts are being used to formulate supplements. However, those extracts are often poorly compactable, making tabletting a challenge. In addition, conveni ent dosage forms, such as orally disintegrating tablets (ODTs), are becoming increasingly popular. As they do not need to be swallowed, they can be taken on-the-go and are particularly suitable for children and the elderly who often struggle to swallow tablets. Challenges for product developers Of paramount concern to formulators of dietary supplements is the requirement to maintain a stable finished product that will release its contents in the gastrointestinal tract at the right time and place, for optimal absorption and utilisation. That’s because undigested and undissolved supplements can create digestive discomfort. It’s therefore essential that tablets are properly formulated and tested to demonstrate compliance. The world of tablet formulation and compression is complex. Not only do companies have to consider dissolution properties, but also address issues such as shelf life, stability and exposure to environmental hazards, including oxygen, light, humidity and high or low temperatures. Plus, they must select appropriate tablet processing aids – excipients – to optimise the compressibility and disintegration of the compound. Tablets such as ODTs can be manufactured using various techniques, including tablet moulding, freeze-drying, spray-drying and direct compression. From a cost and simplicity perspective, the preferred method is direct compression. The key parameter for directly compressed ODTs is compression force. If it is too low, it may improve disintegration but lead to a friable tablet that is not robust enough for handling. Conversely, a compression force that is too high will result in ODTs that do not disperse properly. Thus, an excipient with good compactibility properties is of utmost importance. The right excipient Today’s formulators have access to several directly compressible excipient platforms, each with its own advantages and disadvantages 34 No. 3 November/December 2021

Formulation of nutraceuticals – such as poor compactibility, lack of stability or inferior organoleptic properties. The choice of excipient is therefore crucial. It must be stable, have a good level of inertness, good flowability and compactibility, and also contribute to a pleasant mouthfeel in the final formulation. As it can be difficult to find a multifunctional excipient that combines all of these features, Omya recently launched mineral solutions Omyanutra 300 DC and Omyanutra 300 Flash, both of which are designed to overcome such processing challenges and improve ease of use. Strong, stable and quick to dissolve With Omyanutra 300 DC and Omyanutra 300 Flash, manufacturers can create hard tablets at low compression forces. They allow for free-flowing, directly compressible granules and offer better compactibility compared to benchmark excipients such as lactose and microcrystalline cellulose (graph 1). In addition, the minerals provide fast disintegration thanks to their particles’ porous structure (graph 2). This porosity also enables the safe carrying and release of active ingredients. Omyanutra 300 DC is a granulated, directly compressible version of the company’s proprietary functionalised calcium carbonate excipient. Thanks to a special patented technology, the particle structure and surface morphology become porous. The final particles are characterised by an external lamellar structure and an internal network of interconnected pores. This structure provides plenty of contact points among the particles, ensuring interlocking during compaction, which results in stable mechanical binding. Omyanutra 300 DC therefore improves the compactability of poorly compactable substances, including herbal extracts. Omyanutra 300 Flash comes with an additional superdisintegrant and is a perfect all-in-one solution for manufacturers of orally disintegrating and fast-dissolving tablets (ODTs/FDTs). It provides fast disintegration regardless of the hardness of the solid dosage form. For example, an ODT with Omyanutra 300 Flash completely disintegrates in the mouth in less than 15 seconds. Both ingredients are also free from nanoparticles and GMOs, and made of high-purity, natural mineral material. Cost-efficient production Unlike many similar materials, Omyanutra 300 DC and Omyanutra 300 Flash have the advantage of being biocompatible. They also offer multiple functionalities with very simple chemistry, and enable a straightforward tablet production process. These mineral excipients impart high mechanical strength to tablets, enabling the use of regular bottles as packaging, which significantly reduces the overall cost of production compared with other tablet technologies. R&D expertise on-site Graph 1: Omyanutra 300 DC offers better compactibility compared to lactose and microcrystalline cellulose Keeping all of these advantages in mind, Omyanutra 300 DC and Omyanutra 300 Flash are promising excipients for tablets, especially for ODTs and FDTs. And, with innovation being a key driver in fast-moving markets such as the dietary supplements industry, a flair for upcoming trends and the ability to rapidly convert them into marketable products is vital for successful positioning. With its state-of-the-art in-house laboratory, Omya can quickly react to market needs and deliver a short time-to-market for nutraceutical products. The innovative facility at the company’s headquarters in Oftringen (Switzerland) comprises a wet lab for product development as well as a dry lab for granulation, tabletting and performance analy sis. Furthermore, cutting edge equipment allows for high-quality research into oral solid dosage forms, backed by technical expertise and customer support. For more information, please contact Graph 2: Omyanutra 300 DC provides faster disintegration than lactose and microcrystalline cellulose Tanja Budde, Director Innovation & Technical Marketing - Consumer Goods Javier Camargo,Global Business Development Manager Pharma Omya International AG, Switzerland info.pharma@omya.com www.omya.com No. 3 November/December 2021 35

Wählen Sie die gewünschte Fachzeitschrift

fng MAGAZIN - Food · Nonfood · Getränke · Tobacco